X连锁低磷血症患儿的布罗苏单抗与常规疗法对比:开放标签第3期延长期的结果

IF 3.4 Q2 ENDOCRINOLOGY & METABOLISM JBMR Plus Pub Date : 2024-01-04 DOI:10.1093/jbmrpl/ziad001
Leanne M. Ward, Wolfgang Högler, Francis H. Glorieux, A. Portale, Michael P. Whyte, C. Munns, Ola Nilsson, Jill H Simmons, Raja Padidela, Noriyuki Namba, H. Cheong, Etienne Sochett, Koji Muroya, Hiroyuki Tanaka, P. Pitukcheewanont, G. Gottesman, Andrew Biggin, Farzana Perwad, Angel Chen, J. Lawrence Merritt, Erik A. Imel
{"title":"X连锁低磷血症患儿的布罗苏单抗与常规疗法对比:开放标签第3期延长期的结果","authors":"Leanne M. Ward, Wolfgang Högler, Francis H. Glorieux, A. Portale, Michael P. Whyte, C. Munns, Ola Nilsson, Jill H Simmons, Raja Padidela, Noriyuki Namba, H. Cheong, Etienne Sochett, Koji Muroya, Hiroyuki Tanaka, P. Pitukcheewanont, G. Gottesman, Andrew Biggin, Farzana Perwad, Angel Chen, J. Lawrence Merritt, Erik A. Imel","doi":"10.1093/jbmrpl/ziad001","DOIUrl":null,"url":null,"abstract":"\n In a randomized, open-label phase 3 study of 61 children 1–12 years old with X-linked hypophosphatemia (XLH) previously treated with conventional therapy, changing to bi-weekly (Q2W) burosumab for 64 weeks improved phosphate metabolism, radiographic rickets, and growth compared with conventional therapy. In this open-label extension period (weeks 64–88), 21 children continued burosumab Q2W at the previous dose or crossed over from conventional therapy to burosumab starting at 0.8 mg/kg Q2W and had continued clinical radiographic assessments through week 88. Efficacy endpoints and safety observations were summarized descriptively for the treatment groups (burosumab continuation, n = 6; crossover, n = 15). At week 88 compared with baseline, improvements in the following outcomes were observed in the burosumab continuation and crossover groups, respectively: mean (SD) RGI-C rickets total score (primary outcome), +2.11 (0.27) and + 1.89 (0.35); mean (SD) RGI-C lower limb deformity score, +1.61 (0.91) and + 0.73 (0.82), and mean (SD) height Z-score + 0.41 (0.50) and + 0.08 (0.34). Phosphate metabolism normalized rapidly in the crossover group and persisted in the continuation group. Mean (SD) serum ALP decreased from 169% (43%) of the upper limit of normal (ULN) at baseline to 126% (51%) at week 88 in the continuation group, and from 157% (33%) of the ULN at baseline to 111% (23%) at week 88 in the crossover group. During the extension period, treatment-emergent adverse events (AEs) were reported in all six children in the burosumab continuation group and in 14/15 children in the cross-over group. AE profiles in the randomized and extension periods were similar, with no new safety signals identified. Thus, improvements from baseline in radiographic rickets continued in the extension period among children with XLH who remained on burosumab. Children who crossed over from conventional therapy to burosumab demonstrated rapid improvement in phosphate metabolism and improved rickets healing over the ensuing 22 weeks.","PeriodicalId":14611,"journal":{"name":"JBMR Plus","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Burosumab versus conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period\",\"authors\":\"Leanne M. Ward, Wolfgang Högler, Francis H. Glorieux, A. Portale, Michael P. Whyte, C. Munns, Ola Nilsson, Jill H Simmons, Raja Padidela, Noriyuki Namba, H. Cheong, Etienne Sochett, Koji Muroya, Hiroyuki Tanaka, P. Pitukcheewanont, G. Gottesman, Andrew Biggin, Farzana Perwad, Angel Chen, J. Lawrence Merritt, Erik A. Imel\",\"doi\":\"10.1093/jbmrpl/ziad001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n In a randomized, open-label phase 3 study of 61 children 1–12 years old with X-linked hypophosphatemia (XLH) previously treated with conventional therapy, changing to bi-weekly (Q2W) burosumab for 64 weeks improved phosphate metabolism, radiographic rickets, and growth compared with conventional therapy. In this open-label extension period (weeks 64–88), 21 children continued burosumab Q2W at the previous dose or crossed over from conventional therapy to burosumab starting at 0.8 mg/kg Q2W and had continued clinical radiographic assessments through week 88. Efficacy endpoints and safety observations were summarized descriptively for the treatment groups (burosumab continuation, n = 6; crossover, n = 15). At week 88 compared with baseline, improvements in the following outcomes were observed in the burosumab continuation and crossover groups, respectively: mean (SD) RGI-C rickets total score (primary outcome), +2.11 (0.27) and + 1.89 (0.35); mean (SD) RGI-C lower limb deformity score, +1.61 (0.91) and + 0.73 (0.82), and mean (SD) height Z-score + 0.41 (0.50) and + 0.08 (0.34). Phosphate metabolism normalized rapidly in the crossover group and persisted in the continuation group. Mean (SD) serum ALP decreased from 169% (43%) of the upper limit of normal (ULN) at baseline to 126% (51%) at week 88 in the continuation group, and from 157% (33%) of the ULN at baseline to 111% (23%) at week 88 in the crossover group. During the extension period, treatment-emergent adverse events (AEs) were reported in all six children in the burosumab continuation group and in 14/15 children in the cross-over group. AE profiles in the randomized and extension periods were similar, with no new safety signals identified. Thus, improvements from baseline in radiographic rickets continued in the extension period among children with XLH who remained on burosumab. Children who crossed over from conventional therapy to burosumab demonstrated rapid improvement in phosphate metabolism and improved rickets healing over the ensuing 22 weeks.\",\"PeriodicalId\":14611,\"journal\":{\"name\":\"JBMR Plus\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JBMR Plus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jbmrpl/ziad001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JBMR Plus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jbmrpl/ziad001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

在一项随机、开放标签 3 期研究中,61 名 1-12 岁的 X 连锁低磷血症(XLH)患儿曾接受过常规治疗,与常规治疗相比,改用每两周一次(Q2W)的布罗索单抗治疗 64 周后,磷代谢、影像学佝偻病和生长情况均有所改善。在开放标签延长期(第64-88周)中,21名儿童继续按之前的剂量服用布罗苏单抗Q2W,或从常规疗法过渡到布罗苏单抗,起始剂量为0.8毫克/千克Q2W,并继续进行临床放射学评估直至第88周。对治疗组的疗效终点和安全性观察进行了描述性总结(继续使用布罗苏单抗,n = 6;交叉使用,n = 15)。与基线相比,在第88周时,观察到布罗舒单抗继续治疗组和交叉治疗组的以下结果分别有所改善:RGI-C佝偻病总分(主要结果)的平均值(标度),+2.11 (0.27) 和 + 1.89 (0.35);平均(标清)RGI-C 下肢畸形评分,+1.61 (0.91) 和 + 0.73 (0.82);平均(标清)身高 Z 评分 + 0.41 (0.50) 和 + 0.08 (0.34)。磷酸盐代谢在交叉组中迅速恢复正常,在继续治疗组中持续正常。继续治疗组的血清 ALP 平均值(标度)从基线值正常值上限(ULN)的 169% (43%) 降至第 88 周时的 126% (51%),交叉治疗组的血清 ALP 平均值从基线值正常值上限(ULN)的 157% (33%) 降至第 88 周时的 111% (23%)。在延长期内,布罗舒单抗继续治疗组的所有6名患儿和交叉治疗组的14/15名患儿均报告了治疗突发不良事件(AE)。随机治疗和延长治疗期间的不良反应情况相似,没有发现新的安全信号。因此,在延长期内,继续服用布罗苏单抗的XLH患儿的放射学佝偻病症状与基线相比仍有改善。在随后的22周里,从常规疗法转为使用布罗苏单抗的儿童的磷酸盐代谢迅速改善,佝偻病愈合情况也有所改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Burosumab versus conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period
In a randomized, open-label phase 3 study of 61 children 1–12 years old with X-linked hypophosphatemia (XLH) previously treated with conventional therapy, changing to bi-weekly (Q2W) burosumab for 64 weeks improved phosphate metabolism, radiographic rickets, and growth compared with conventional therapy. In this open-label extension period (weeks 64–88), 21 children continued burosumab Q2W at the previous dose or crossed over from conventional therapy to burosumab starting at 0.8 mg/kg Q2W and had continued clinical radiographic assessments through week 88. Efficacy endpoints and safety observations were summarized descriptively for the treatment groups (burosumab continuation, n = 6; crossover, n = 15). At week 88 compared with baseline, improvements in the following outcomes were observed in the burosumab continuation and crossover groups, respectively: mean (SD) RGI-C rickets total score (primary outcome), +2.11 (0.27) and + 1.89 (0.35); mean (SD) RGI-C lower limb deformity score, +1.61 (0.91) and + 0.73 (0.82), and mean (SD) height Z-score + 0.41 (0.50) and + 0.08 (0.34). Phosphate metabolism normalized rapidly in the crossover group and persisted in the continuation group. Mean (SD) serum ALP decreased from 169% (43%) of the upper limit of normal (ULN) at baseline to 126% (51%) at week 88 in the continuation group, and from 157% (33%) of the ULN at baseline to 111% (23%) at week 88 in the crossover group. During the extension period, treatment-emergent adverse events (AEs) were reported in all six children in the burosumab continuation group and in 14/15 children in the cross-over group. AE profiles in the randomized and extension periods were similar, with no new safety signals identified. Thus, improvements from baseline in radiographic rickets continued in the extension period among children with XLH who remained on burosumab. Children who crossed over from conventional therapy to burosumab demonstrated rapid improvement in phosphate metabolism and improved rickets healing over the ensuing 22 weeks.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JBMR Plus
JBMR Plus Medicine-Orthopedics and Sports Medicine
CiteScore
5.80
自引率
2.60%
发文量
103
审稿时长
8 weeks
期刊最新文献
Evaluating the relationship between glycemic control and bone fragility within the UK Biobank: observational and one-sample Mendelian randomization analyses. Correction to: Prevalence and risk factors for atypical femoral fracture among Lebanese patients with hip and shaft fractures. In nondiabetic C57BL/6J mice, canagliflozin affects the skeleton in a sex- and age-dependent manner. Genotype-phenotype correlations in 294 pediatric patients with osteogenesis imperfecta. Prevalence of chondrocalcinosis and calcium pyrophosphate deposition disease in a cohort of adult patients with low alkaline phosphatase levels and a positive versus negative genetic ALPL study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1